These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23880711)

  • 21. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit.
    Bal O; Oksuzoglu B; Dogan M; Durnali A; Uyeturk U; Demirci A; Arslan UY; Ekinci AS; Yildirim N; Alkis N; Kilic S
    Ir J Med Sci; 2020 Aug; 189(3):805-810. PubMed ID: 31823174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
    Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "The use of bisphosphonates to treat skeletal complications in solid tumours".
    D'Oronzo S; Wood S; Brown JE
    Bone; 2021 Jun; 147():115907. PubMed ID: 33676057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
    Kohno N
    Int J Clin Oncol; 2008 Feb; 13(1):18-23. PubMed ID: 18307015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
    Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
    Dorff TB; Agarwal N
    Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
    Carter JA; Joshi AD; Kaura S; Botteman MF
    Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
    Gnant M; Clézardin P
    Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates for advanced prostate cancer.
    Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A
    J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
    [No Abstract]   [Full Text] [Related]  

  • 36. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials.
    Gnant M
    Curr Cancer Drug Targets; 2009 Nov; 9(7):824-33. PubMed ID: 20025570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates and metastatic bone disease.
    Barni S; Mandalà M; Cazzaniga M; Cabiddu M; Cremonesi M
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii91-95. PubMed ID: 16608996
    [No Abstract]   [Full Text] [Related]  

  • 38. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonates in metastatic bone disease: renal safety matters.
    Body JJ
    Oncologist; 2005; 10 Suppl 1():1-2. PubMed ID: 16264105
    [No Abstract]   [Full Text] [Related]  

  • 40. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
    Saad F; Colombel M
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.